Literature DB >> 22293561

Ruxolitinib.

Ruben A Mesa, Uma Yasothan, Peter Kirkpatrick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22293561     DOI： 10.1038/nrd3652

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  8 in total

1.  Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report.

Authors:  Richard T Silver; Katherine Vandris; Joshua J Goldman
Journal:  Blood       Date:  2011-04-25       Impact factor: 22.113

Review 2.  Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Jorge Cortes; Srdan Verstovsek
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

Review 3.  Advances in understanding and management of myeloproliferative neoplasms.

Authors:  Alessandro M Vannucchi; Paola Guglielmelli; Ayalew Tefferi
Journal:  CA Cancer J Clin       Date:  2009-04-15       Impact factor: 508.702

4.  Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients.

Authors:  Francisco Cervantes; Alberto Alvarez-Larrán; Abel Domingo; Eduardo Arellano-Rodrigo; Emili Montserrat
Journal:  Br J Haematol       Date:  2005-06       Impact factor: 6.998

5.  Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903.

Authors:  Ruben A Mesa; Xiaopan Yao; Larry D Cripe; Chin Yang Li; Mark Litzow; Elisabeth Paietta; Jacob M Rowe; Ayalew Tefferi; Martin S Tallman
Journal:  Blood       Date:  2010-07-22       Impact factor: 22.113

6.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Authors:  Srdan Verstovsek; Hagop Kantarjian; Ruben A Mesa; Animesh D Pardanani; Jorge Cortes-Franco; Deborah A Thomas; Zeev Estrov; Jordan S Fridman; Edward C Bradley; Susan Erickson-Viitanen; Kris Vaddi; Richard Levy; Ayalew Tefferi
Journal:  N Engl J Med       Date:  2010-09-16       Impact factor: 91.245

7.  Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.

Authors:  Alfonso Quintás-Cardama; Kris Vaddi; Phillip Liu; Taghi Manshouri; Jun Li; Peggy A Scherle; Eian Caulder; Xiaoming Wen; Yanlong Li; Paul Waeltz; Mark Rupar; Timothy Burn; Yvonne Lo; Jennifer Kelley; Maryanne Covington; Stacey Shepard; James D Rodgers; Patrick Haley; Hagop Kantarjian; Jordan S Fridman; Srdan Verstovsek
Journal:  Blood       Date:  2010-02-03       Impact factor: 22.113

8.  Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).

Authors:  Sylvain Thepot; Raphael Itzykson; Valerie Seegers; Emmanuel Raffoux; Bruno Quesnel; Yasmine Chait; Lucile Sorin; Francois Dreyfus; Thomas Cluzeau; Jacques Delaunay; Laurence Sanhes; Virginie Eclache; Caroline Dartigeas; Pascal Turlure; Stephanie Harel; Celia Salanoubat; Jean-Jacques Kiladjian; Pierre Fenaux; Lionel Adès
Journal:  Blood       Date:  2010-07-27       Impact factor: 22.113
  8 in total
  53 in total

Review 1.  HiJAKing the epigenome in leukemia and lymphoma.

Authors:  Amanda C Drennan; Lixin Rui
Journal:  Leuk Lymphoma       Date:  2017-04-12

Review 2.  Vitiligo Pathogenesis and Emerging Treatments.

Authors:  Mehdi Rashighi; John E Harris
Journal:  Dermatol Clin       Date:  2017-04       Impact factor: 3.478

3.  The discovery of medicines for rare diseases.

Authors:  David C Swinney; Shuangluo Xia
Journal:  Future Med Chem       Date:  2014-06       Impact factor: 3.808

Review 4.  Interferons and their stimulated genes in the tumor microenvironment.

Authors:  Hyeonjoo Cheon; Ernest C Borden; George R Stark
Journal:  Semin Oncol       Date:  2014-02-14       Impact factor: 4.929

5.  Beryllium-induced lung disease exhibits expression profiles similar to sarcoidosis.

Authors:  Li Li; Lori J Silveira; Nabeel Hamzeh; May Gillespie; Peggy M Mroz; Annyce S Mayer; Tasha E Fingerlin; Lisa A Maier
Journal:  Eur Respir J       Date:  2016-04-21       Impact factor: 16.671

Review 6.  The promise of Janus kinase inhibitors in the treatment of hematological malignancies.

Authors:  Emilee Senkevitch; Scott Durum
Journal:  Cytokine       Date:  2016-10-27       Impact factor: 3.861

Review 7.  Interleukins in glioblastoma pathophysiology: implications for therapy.

Authors:  Y T Yeung; K L McDonald; T Grewal; L Munoz
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

Review 8.  Targeting tumour-supportive cellular machineries in anticancer drug development.

Authors:  Matthias Dobbelstein; Ute Moll
Journal:  Nat Rev Drug Discov       Date:  2014-03       Impact factor: 84.694

Review 9.  Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies.

Authors:  D Sia; V Tovar; A Moeini; J M Llovet
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

10.  Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.

Authors:  Anas Younes; Jorge Romaguera; Michelle Fanale; Peter McLaughlin; Frederick Hagemeister; Amanda Copeland; Sattva Neelapu; Larry Kwak; Jatin Shah; Silvana de Castro Faria; Stefan Hart; Jeanette Wood; Ramesh Jayaraman; Kantharaj Ethirajulu; Joy Zhu
Journal:  J Clin Oncol       Date:  2012-09-10       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.